noom with glp-1 offers cut-price compounded drug for obesity Noom expands its GLP-1 range
Description
Among those initiating addon therapy, 40.7% of metformin users added SGLT2 inhibitors, 36.0% added GLP1 receptor agonists (RAs), 14.0% added dipeptidyl peptidase 4 (DPP4) inhibitors, 6% added insulin, and 3.3% added sulfonylureas
doi:10.1210/er.2015-1084 9
Although bone turnover markers CTX and P1NP declined, differences among groups were not statistically significant
If progress plateaus or a side effect nags, the plan can be adjusted rather than abandoned
Mousa HH, Sharawy MH, Nader MA
But allergic reaction to Januvia has been reported since the drug became available on the market
